Paper Details

  1. Home
  2. Paper Details

Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change.

Author: BaldoFrancesco, BarbiEgidio, BrunoIrene, MagnolatoAndrea

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Selumetinib, an inhibitor of mitogen-activated protein kinase (MEK) 1 and 2, effectively tackles the growth of plexiform neurofibromas (PNs). The most common side effects are mild to moderate and include gastrointestinal symptoms, dermatologic manifestations, and laboratory test abnormalities.
Paper Details　
Original Abstract of the Article :
Plexiform neurofibromas (PNs) are congenital tumors that affect around 50 % of the subjects with neurofibromatosis type 1. Despite being histologically benign, PNs can grow rapidly, especially in the pediatric age, and cause severe morbidities. In the past, various therapeutic approaches have been p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866429/

データ提供：米国国立医学図書館（NLM）

Selumetinib: A New Hope for Plexiform Neurofibromas

The field of oncology is constantly searching for effective treatments for challenging conditions like plexiform neurofibromas (PNs), benign tumors that can cause significant problems for patients. This research investigates the use of selumetinib, a new drug, in treating PNs, especially in children.

The study focuses on the safety and effectiveness of selumetinib in treating PNs, a rare type of tumor that affects individuals with neurofibromatosis type 1. The researchers report the first documented cases of peripheral edema and hair color change as side effects of selumetinib. They highlight the drug's potential in controlling PN growth while acknowledging the need for further research to optimize its use.

Understanding the Side Effects of Selumetinib

The study provides crucial information for clinicians and patients considering selumetinib for PN treatment. It's important to understand the potential side effects, such as peripheral edema and hair color change, and discuss these with your doctor to make informed decisions. It's like carefully navigating a desert, where you need to be aware of the potential hazards to ensure a safe journey.

Navigating the Terrain of Side Effects

The discovery of selumetinib's side effects emphasizes the importance of ongoing research in the field of oncology. As we continue to explore new treatments for challenging conditions, we must always prioritize patient safety and well-being. It's like trekking through a vast desert, where we need to proceed with caution and carefully evaluate each step to ensure a successful journey.

Dr. Camel's Conclusion

Selumetinib holds promise as a potential treatment for PNs, but further research is needed to better understand its long-term effects and develop strategies to manage any potential side effects. It's a reminder that even in the vast and challenging landscape of medicine, we must continue to explore and innovate to find solutions for our patients.

Date :
  1. Date Completed 2021-05-27
  2. Date Revised 2021-05-27
Further Info :

Pubmed ID

33549085

DOI: Digital Object Identifier

PMC7866429

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.